Zevra therapeutics announces top-line data from the phase 2 clinical trial of kp1077 for idiopathic hypersomnia

Kp1077 demonstrates clinically meaningful benefits for key ih symptoms top-line data provide key information for the design of a phase 3 study celebration, fla., march 26, 2024 (globe newswire) -- zevra therapeutics, inc. (nasdaqgs: zvra) (zevra, or the company) a rare disease therapeutics company, today announced top-line data from its placebo-controlled, double-blind phase 2 clinical trial (nct05668754) evaluating the safety and tolerability of kp1077 (serdexmethylphenidate, or sdx) in patients with idiopathic hypersomnia (ih).
ZVRA Ratings Summary
ZVRA Quant Ranking